| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Nasal Polyps | 34 | 2021 | 221 | 10.32 | Why? |
| Rhinitis | 39 | 2021 | 626 | 8.30 | Why? |
| Sinusitis | 40 | 2021 | 649 | 8.19 | Why? |
| Rhinitis, Allergic | 21 | 2021 | 704 | 2.88 | Why? |
| Staphylococcus aureus | 11 | 2019 | 844 | 2.21 | Why? |
| Nasal Mucosa | 10 | 2019 | 1218 | 1.97 | Why? |
| Enterotoxins | 5 | 2019 | 115 | 1.86 | Why? |
| Asthma | 26 | 2021 | 4383 | 1.70 | Why? |
| Allergens | 9 | 2019 | 728 | 1.60 | Why? |
| Staphylococcal Infections | 8 | 2019 | 1099 | 1.55 | Why? |
| Immunoglobulin E | 12 | 2020 | 557 | 1.25 | Why? |
| Chronic Disease | 33 | 2021 | 5139 | 1.13 | Why? |
| Hypersensitivity | 9 | 2021 | 1137 | 1.02 | Why? |
| Anti-Allergic Agents | 4 | 2019 | 167 | 1.00 | Why? |
| Rhinitis, Allergic, Seasonal | 5 | 2017 | 121 | 0.94 | Why? |
| Sublingual Immunotherapy | 2 | 2020 | 88 | 0.86 | Why? |
| Hypersensitivity, Immediate | 2 | 2019 | 134 | 0.81 | Why? |
| Eosinophils | 6 | 2020 | 848 | 0.81 | Why? |
| Th2 Cells | 4 | 2020 | 680 | 0.79 | Why? |
| Dermatophagoides pteronyssinus | 1 | 2018 | 3 | 0.78 | Why? |
| Receptors, Interleukin-1 Type I | 1 | 2018 | 18 | 0.78 | Why? |
| Surgical Tape | 1 | 2018 | 8 | 0.77 | Why? |
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 59 | 0.77 | Why? |
| Antigens, Dermatophagoides | 1 | 2018 | 25 | 0.76 | Why? |
| Endoscopy | 4 | 2019 | 1564 | 0.75 | Why? |
| Nose Diseases | 1 | 2020 | 139 | 0.72 | Why? |
| Interleukin-5 | 4 | 2019 | 138 | 0.69 | Why? |
| Cell Adhesion Molecules | 2 | 2017 | 472 | 0.68 | Why? |
| Interleukins | 2 | 2018 | 762 | 0.61 | Why? |
| Immunotherapy | 3 | 2017 | 2421 | 0.58 | Why? |
| Skin Tests | 4 | 2019 | 229 | 0.55 | Why? |
| Th17 Cells | 1 | 2019 | 657 | 0.53 | Why? |
| Antibodies, Monoclonal, Humanized | 8 | 2020 | 9335 | 0.48 | Why? |
| Dysbiosis | 1 | 2018 | 685 | 0.47 | Why? |
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 657 | 0.46 | Why? |
| Nose | 1 | 2018 | 1093 | 0.45 | Why? |
| Phagocytosis | 2 | 2019 | 409 | 0.40 | Why? |
| Mobile Applications | 9 | 2019 | 3032 | 0.40 | Why? |
| Quality of Life | 9 | 2019 | 9820 | 0.38 | Why? |
| Epithelial Cells | 2 | 2018 | 3508 | 0.38 | Why? |
| Mites | 2 | 2019 | 26 | 0.37 | Why? |
| Paranasal Sinus Diseases | 1 | 2008 | 39 | 0.37 | Why? |
| Desensitization, Immunologic | 3 | 2018 | 574 | 0.35 | Why? |
| Histamine H1 Antagonists | 2 | 2019 | 79 | 0.35 | Why? |
| Extracellular Traps | 1 | 2017 | 1036 | 0.35 | Why? |
| Omalizumab | 3 | 2019 | 158 | 0.34 | Why? |
| Doxycycline | 2 | 2017 | 307 | 0.34 | Why? |
| DNA, Catalytic | 2 | 2018 | 48 | 0.33 | Why? |
| Work Performance | 3 | 2017 | 186 | 0.33 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.33 | Why? |
| Interferons | 1 | 2018 | 2885 | 0.31 | Why? |
| Lymphocytes | 1 | 2018 | 3056 | 0.30 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.29 | Why? |
| Apoptosis | 2 | 2017 | 2335 | 0.28 | Why? |
| Adult | 37 | 2019 | 244371 | 0.28 | Why? |
| Wound Healing | 1 | 2008 | 424 | 0.27 | Why? |
| Nasal Provocation Tests | 1 | 2003 | 12 | 0.27 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.27 | Why? |
| Nasal Lavage Fluid | 1 | 2003 | 43 | 0.27 | Why? |
| Case-Control Studies | 9 | 2019 | 17671 | 0.26 | Why? |
| Cytokines | 6 | 2018 | 15010 | 0.25 | Why? |
| Humans | 93 | 2021 | 930598 | 0.25 | Why? |
| Middle Aged | 33 | 2020 | 270681 | 0.25 | Why? |
| Rhinovirus | 2 | 2018 | 979 | 0.24 | Why? |
| Dermatitis, Atopic | 3 | 2019 | 714 | 0.24 | Why? |
| Drug-Eluting Stents | 1 | 2008 | 562 | 0.24 | Why? |
| Male | 42 | 2021 | 367725 | 0.23 | Why? |
| Female | 43 | 2020 | 380317 | 0.23 | Why? |
| Otolaryngology | 4 | 2020 | 1917 | 0.23 | Why? |
| Phytotherapy | 1 | 2009 | 743 | 0.23 | Why? |
| Aerosols | 1 | 2017 | 5393 | 0.21 | Why? |
| Environmental Medicine | 1 | 2020 | 21 | 0.21 | Why? |
| Paranasal Sinuses | 2 | 2018 | 217 | 0.20 | Why? |
| Young Adult | 18 | 2019 | 93724 | 0.20 | Why? |
| Nasal Surgical Procedures | 1 | 2020 | 102 | 0.19 | Why? |
| Cell Phone | 2 | 2017 | 750 | 0.19 | Why? |
| September 11 Terrorist Attacks | 1 | 2018 | 14 | 0.19 | Why? |
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2018 | 29 | 0.19 | Why? |
| Placebos | 2 | 2019 | 629 | 0.19 | Why? |
| Nasopharyngeal Neoplasms | 1 | 2019 | 64 | 0.19 | Why? |
| Paracrine Communication | 1 | 2019 | 73 | 0.19 | Why? |
| Activin Receptors | 1 | 2018 | 1 | 0.19 | Why? |
| Paranasal Sinus Neoplasms | 1 | 2019 | 55 | 0.19 | Why? |
| Rescue Work | 1 | 2018 | 47 | 0.19 | Why? |
| Tertiary Lymphoid Structures | 1 | 2017 | 6 | 0.18 | Why? |
| Multimorbidity | 3 | 2019 | 703 | 0.18 | Why? |
| Epidermis | 1 | 2018 | 47 | 0.18 | Why? |
| Lolium | 1 | 2017 | 2 | 0.18 | Why? |
| Poaceae | 1 | 2017 | 23 | 0.18 | Why? |
| Eosinophilia | 2 | 2018 | 292 | 0.18 | Why? |
| Mucositis | 1 | 2018 | 40 | 0.18 | Why? |
| Bacterial Proteins | 2 | 2017 | 1318 | 0.18 | Why? |
| Firefighters | 1 | 2018 | 93 | 0.18 | Why? |
| Uncoupling Agents | 1 | 2017 | 3 | 0.18 | Why? |
| Common Cold | 2 | 2021 | 645 | 0.17 | Why? |
| Conjunctivitis | 2 | 2019 | 318 | 0.17 | Why? |
| Patient Advocacy | 1 | 2019 | 173 | 0.17 | Why? |
| Histamine Antagonists | 1 | 2019 | 203 | 0.17 | Why? |
| Plant Extracts | 1 | 2009 | 1514 | 0.17 | Why? |
| Organophosphorus Compounds | 1 | 2017 | 53 | 0.17 | Why? |
| Efficiency | 2 | 2019 | 420 | 0.17 | Why? |
| Respiratory Physiological Phenomena | 1 | 2018 | 157 | 0.17 | Why? |
| Oxidative Phosphorylation | 1 | 2017 | 120 | 0.17 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 92 | 0.17 | Why? |
| T-Lymphocytes, Helper-Inducer | 2 | 2017 | 497 | 0.17 | Why? |
| Tablets | 1 | 2017 | 219 | 0.16 | Why? |
| Pollen | 1 | 2017 | 137 | 0.16 | Why? |
| Adrenal Cortex Hormones | 5 | 2021 | 6537 | 0.16 | Why? |
| Tight Junctions | 1 | 2018 | 179 | 0.16 | Why? |
| Lung Diseases | 1 | 2010 | 2361 | 0.16 | Why? |
| Heterocyclic Compounds | 1 | 2017 | 64 | 0.16 | Why? |
| GATA3 Transcription Factor | 1 | 2015 | 16 | 0.16 | Why? |
| Lactococcus lactis | 1 | 2015 | 45 | 0.16 | Why? |
| Pulmonary Ventilation | 1 | 2018 | 152 | 0.16 | Why? |
| Immunization | 4 | 2019 | 2019 | 0.16 | Why? |
| Cancer Vaccines | 1 | 2017 | 136 | 0.15 | Why? |
| Interleukin-33 | 1 | 2017 | 120 | 0.15 | Why? |
| Goals | 1 | 2019 | 335 | 0.15 | Why? |
| Organisms, Genetically Modified | 1 | 2015 | 59 | 0.15 | Why? |
| Comorbidity | 7 | 2020 | 34796 | 0.15 | Why? |
| Adolescent | 14 | 2019 | 86841 | 0.15 | Why? |
| Serine Proteases | 1 | 2017 | 211 | 0.15 | Why? |
| Rhinitis, Allergic, Perennial | 2 | 2017 | 36 | 0.15 | Why? |
| Severity of Illness Index | 7 | 2019 | 48226 | 0.15 | Why? |
| Diet | 2 | 2018 | 2052 | 0.15 | Why? |
| DNA Damage | 1 | 2017 | 285 | 0.15 | Why? |
| Delivery of Health Care, Integrated | 2 | 2017 | 1549 | 0.15 | Why? |
| Cell Death | 1 | 2017 | 536 | 0.14 | Why? |
| Capillary Permeability | 1 | 2017 | 277 | 0.14 | Why? |
| Aged | 17 | 2021 | 215776 | 0.14 | Why? |
| Allergists | 3 | 2021 | 266 | 0.14 | Why? |
| Necrosis | 1 | 2017 | 532 | 0.14 | Why? |
| Protein Array Analysis | 1 | 2017 | 387 | 0.14 | Why? |
| Patient Participation | 2 | 2019 | 829 | 0.14 | Why? |
| Interleukin-17 | 1 | 2019 | 602 | 0.14 | Why? |
| Antigens, Bacterial | 1 | 2017 | 330 | 0.13 | Why? |
| Irritants | 1 | 2013 | 28 | 0.13 | Why? |
| Mast Cells | 1 | 2017 | 370 | 0.13 | Why? |
| Visual Analog Scale | 3 | 2019 | 151 | 0.13 | Why? |
| Benzalkonium Compounds | 1 | 2013 | 42 | 0.13 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.13 | Why? |
| Cells, Cultured | 3 | 2019 | 5835 | 0.13 | Why? |
| Smartphone | 3 | 2019 | 1840 | 0.13 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 120 | 0.12 | Why? |
| Patient Reported Outcome Measures | 1 | 2019 | 912 | 0.12 | Why? |
| Flavonoids | 1 | 2018 | 492 | 0.12 | Why? |
| Decision Support Systems, Clinical | 1 | 2018 | 551 | 0.12 | Why? |
| Follow-Up Studies | 6 | 2019 | 17020 | 0.12 | Why? |
| Biological Therapy | 1 | 2017 | 456 | 0.12 | Why? |
| Immune Tolerance | 1 | 2017 | 608 | 0.12 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.12 | Why? |
| Airway Obstruction | 1 | 2014 | 182 | 0.12 | Why? |
| Regression Analysis | 1 | 2019 | 2484 | 0.11 | Why? |
| Population Surveillance | 3 | 2017 | 4967 | 0.11 | Why? |
| Belgium | 1 | 2018 | 2064 | 0.11 | Why? |
| Anaphylaxis | 1 | 2021 | 940 | 0.11 | Why? |
| DNA | 1 | 2017 | 778 | 0.11 | Why? |
| Sodium Chloride | 1 | 2013 | 203 | 0.11 | Why? |
| Pilot Projects | 5 | 2018 | 5182 | 0.11 | Why? |
| Animals | 13 | 2019 | 78931 | 0.11 | Why? |
| Mucus | 1 | 2013 | 183 | 0.11 | Why? |
| Respiratory Mucosa | 2 | 2019 | 1522 | 0.11 | Why? |
| Loratadine | 1 | 2010 | 18 | 0.11 | Why? |
| Histamine H1 Antagonists, Non-Sedating | 1 | 2010 | 33 | 0.11 | Why? |
| RNA | 1 | 2018 | 1278 | 0.11 | Why? |
| Europe | 8 | 2019 | 12702 | 0.11 | Why? |
| Precision Medicine | 2 | 2017 | 1477 | 0.10 | Why? |
| Tumor Necrosis Factor-alpha | 2 | 2018 | 2483 | 0.10 | Why? |
| Self Care | 1 | 2018 | 918 | 0.10 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.10 | Why? |
| Drug Hypersensitivity | 1 | 2015 | 401 | 0.10 | Why? |
| Plant Roots | 1 | 2009 | 108 | 0.09 | Why? |
| Gene Expression Regulation | 2 | 2018 | 4020 | 0.09 | Why? |
| Treatment Outcome | 6 | 2019 | 51732 | 0.09 | Why? |
| Disease Management | 4 | 2018 | 6841 | 0.09 | Why? |
| Cross-Sectional Studies | 7 | 2019 | 53120 | 0.09 | Why? |
| Inflammation Mediators | 1 | 2019 | 2654 | 0.08 | Why? |
| Aspirin | 1 | 2015 | 1043 | 0.08 | Why? |
| Consensus | 2 | 2021 | 6345 | 0.08 | Why? |
| Child | 9 | 2019 | 70012 | 0.08 | Why? |
| Prevalence | 6 | 2019 | 25773 | 0.08 | Why? |
| Risk | 1 | 2019 | 5288 | 0.08 | Why? |
| Longitudinal Studies | 2 | 2019 | 9893 | 0.08 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.08 | Why? |
| Biomarkers | 3 | 2019 | 23361 | 0.08 | Why? |
| Feeding Behavior | 1 | 2018 | 1909 | 0.08 | Why? |
| Smoking | 1 | 2019 | 3358 | 0.08 | Why? |
| B-Lymphocytes | 2 | 2017 | 4418 | 0.08 | Why? |
| Proteomics | 1 | 2017 | 2481 | 0.07 | Why? |
| Disease Progression | 4 | 2018 | 13580 | 0.07 | Why? |
| Cross Reactions | 1 | 2017 | 4374 | 0.07 | Why? |
| Parents | 1 | 2019 | 2758 | 0.07 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.07 | Why? |
| Endothelium, Vascular | 1 | 2017 | 1751 | 0.07 | Why? |
| Peptides | 1 | 2017 | 2513 | 0.07 | Why? |
| Administration, Intranasal | 2 | 2020 | 1132 | 0.07 | Why? |
| Antibody Formation | 1 | 2017 | 4038 | 0.07 | Why? |
| Clinical Trials as Topic | 2 | 2017 | 7330 | 0.06 | Why? |
| T-Lymphocytes | 2 | 2017 | 6670 | 0.06 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.06 | Why? |
| Mice, Knockout | 2 | 2018 | 1815 | 0.06 | Why? |
| Phenotype | 3 | 2019 | 4037 | 0.06 | Why? |
| Risk Factors | 7 | 2019 | 71621 | 0.06 | Why? |
| Evidence-Based Practice | 2 | 2018 | 693 | 0.06 | Why? |
| Acute Disease | 2 | 2019 | 6029 | 0.06 | Why? |
| Surveys and Questionnaires | 6 | 2018 | 43792 | 0.06 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.06 | Why? |
| Ambulatory Care | 1 | 2019 | 4947 | 0.06 | Why? |
| Drug Evaluation, Preclinical | 1 | 2013 | 3347 | 0.06 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.06 | Why? |
| Antibodies, Monoclonal | 2 | 2017 | 8041 | 0.05 | Why? |
| Inflammation | 3 | 2018 | 13255 | 0.05 | Why? |
| User-Computer Interface | 2 | 2018 | 1068 | 0.05 | Why? |
| Radiography | 1 | 2009 | 1576 | 0.05 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.05 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.05 | Why? |
| Reference Values | 1 | 2003 | 795 | 0.05 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Immunity, Mucosal | 1 | 2003 | 426 | 0.05 | Why? |
| Occupational Exposure | 1 | 2018 | 4742 | 0.05 | Why? |
| Germany | 3 | 2020 | 9196 | 0.05 | Why? |
| Interleukin-4 Receptor alpha Subunit | 1 | 2019 | 46 | 0.05 | Why? |
| Epinephrine | 1 | 2021 | 323 | 0.05 | Why? |
| Respiratory Function Tests | 2 | 2018 | 1755 | 0.05 | Why? |
| Eosinophilic Esophagitis | 1 | 2019 | 35 | 0.05 | Why? |
| Clinical Decision-Making | 3 | 2017 | 3755 | 0.05 | Why? |
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2019 | 38 | 0.05 | Why? |
| Prospective Studies | 5 | 2018 | 43301 | 0.05 | Why? |
| Biopsy | 2 | 2018 | 2811 | 0.05 | Why? |
| Internet | 1 | 2017 | 6204 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2019 | 10649 | 0.05 | Why? |
| Theranostic Nanomedicine | 1 | 2019 | 143 | 0.05 | Why? |
| Receptors, CXCR5 | 1 | 2017 | 35 | 0.05 | Why? |
| Tumor Escape | 1 | 2017 | 36 | 0.05 | Why? |
| Drug Implants | 1 | 2017 | 43 | 0.04 | Why? |
| Immunohistochemistry | 2 | 2018 | 2275 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2019 | 6817 | 0.04 | Why? |
| Information Technology | 1 | 2021 | 278 | 0.04 | Why? |
| Conjunctivitis, Allergic | 1 | 2019 | 94 | 0.04 | Why? |
| Chromans | 1 | 2017 | 8 | 0.04 | Why? |
| Anthocyanins | 1 | 2018 | 51 | 0.04 | Why? |
| Keratinocytes | 1 | 2018 | 119 | 0.04 | Why? |
| Phosphatidylserines | 1 | 2017 | 99 | 0.04 | Why? |
| Receptors, Cytokine | 1 | 2017 | 75 | 0.04 | Why? |
| Dust | 1 | 2018 | 178 | 0.04 | Why? |
| Presenteeism | 1 | 2017 | 63 | 0.04 | Why? |
| Research Design | 3 | 2018 | 5830 | 0.04 | Why? |
| Anthropometry | 1 | 2018 | 233 | 0.04 | Why? |
| Gene-Environment Interaction | 1 | 2017 | 127 | 0.04 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.04 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 6653 | 0.04 | Why? |
| Dilatation | 1 | 2017 | 181 | 0.04 | Why? |
| Signal Transduction | 3 | 2018 | 7207 | 0.04 | Why? |
| Bacteriophages | 1 | 2019 | 268 | 0.04 | Why? |
| Injections | 1 | 2017 | 237 | 0.04 | Why? |
| Vital Capacity | 1 | 2018 | 399 | 0.04 | Why? |
| Delivery of Health Care | 2 | 2019 | 15909 | 0.04 | Why? |
| Absenteeism | 1 | 2017 | 287 | 0.04 | Why? |
| Surgery, Computer-Assisted | 1 | 2017 | 183 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2019 | 88759 | 0.04 | Why? |
| Respiratory Sounds | 1 | 2018 | 294 | 0.04 | Why? |
| Retrospective Studies | 4 | 2019 | 105322 | 0.04 | Why? |
| Otolaryngologists | 1 | 2020 | 533 | 0.04 | Why? |
| Vascular Endothelial Growth Factor B | 1 | 2013 | 3 | 0.03 | Why? |
| Germinal Center | 1 | 2017 | 332 | 0.03 | Why? |
| Spirometry | 1 | 2018 | 524 | 0.03 | Why? |
| Medical Records | 1 | 2017 | 513 | 0.03 | Why? |
| Species Specificity | 1 | 2018 | 1356 | 0.03 | Why? |
| Public Health Surveillance | 2 | 2018 | 3129 | 0.03 | Why? |
| Gastropoda | 1 | 2013 | 15 | 0.03 | Why? |
| Research | 2 | 2017 | 2115 | 0.03 | Why? |
| Symptom Assessment | 2 | 2019 | 4967 | 0.03 | Why? |
| World Health Organization | 2 | 2017 | 4213 | 0.03 | Why? |
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 66 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.03 | Why? |
| Nutrition Assessment | 1 | 2018 | 527 | 0.03 | Why? |
| Mice | 3 | 2018 | 21357 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Toxicity Tests | 1 | 2013 | 100 | 0.03 | Why? |
| Food Hypersensitivity | 1 | 2019 | 397 | 0.03 | Why? |
| Argentina | 1 | 2017 | 1141 | 0.03 | Why? |
| Antibodies, Bacterial | 1 | 2017 | 510 | 0.03 | Why? |
| North America | 1 | 2017 | 1400 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Anti-Asthmatic Agents | 1 | 2017 | 427 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2013 | 11304 | 0.03 | Why? |
| Organ Specificity | 1 | 2017 | 1070 | 0.03 | Why? |
| Health Plan Implementation | 1 | 2017 | 571 | 0.03 | Why? |
| Virulence | 1 | 2019 | 2172 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.03 | Why? |
| Epigenesis, Genetic | 1 | 2017 | 711 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2017 | 1165 | 0.03 | Why? |
| Telemedicine | 2 | 2019 | 25032 | 0.03 | Why? |
| Age Factors | 3 | 2017 | 21039 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.03 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.03 | Why? |
| China | 1 | 2017 | 50654 | 0.03 | Why? |
| Biological Assay | 1 | 2013 | 367 | 0.03 | Why? |
| Asia | 1 | 2017 | 2399 | 0.03 | Why? |
| General Practice | 1 | 2019 | 718 | 0.03 | Why? |
| Child, Preschool | 3 | 2019 | 36283 | 0.03 | Why? |
| Polymorphism, Genetic | 1 | 2017 | 1074 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2018 | 1061 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2013 | 867 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Probiotics | 1 | 2017 | 694 | 0.02 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.02 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.02 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2013 | 604 | 0.02 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.02 | Why? |
| Single-Blind Method | 1 | 2013 | 1283 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Geriatric Assessment | 1 | 2017 | 1372 | 0.02 | Why? |
| Critical Pathways | 1 | 2019 | 1587 | 0.02 | Why? |
| Immunomodulation | 1 | 2017 | 1472 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 7868 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.02 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.02 | Why? |
| Pain Measurement | 1 | 2010 | 533 | 0.02 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.02 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.02 | Why? |
| Head and Neck Neoplasms | 1 | 2019 | 1568 | 0.02 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.02 | Why? |
| Republic of Korea | 1 | 2019 | 5858 | 0.02 | Why? |
| Methylprednisolone | 1 | 2017 | 2107 | 0.02 | Why? |
| Turkey | 1 | 2017 | 3937 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Biological Products | 1 | 2021 | 2331 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2019 | 3228 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2018 | 51949 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2018 | 13720 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.02 | Why? |
| Specimen Handling | 1 | 2003 | 6190 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.02 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2017 | 3567 | 0.02 | Why? |
| Data Collection | 1 | 2014 | 1769 | 0.02 | Why? |
| New York City | 1 | 2018 | 7432 | 0.02 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.02 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.02 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.02 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Membrane Proteins | 1 | 2013 | 1733 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Sensitivity and Specificity | 1 | 2003 | 22971 | 0.01 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.01 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.01 | Why? |
| Triage | 1 | 2021 | 7151 | 0.01 | Why? |
| Aging | 1 | 2017 | 3581 | 0.01 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.01 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.01 | Why? |
| Infant, Newborn | 1 | 2019 | 23105 | 0.01 | Why? |
| Infant | 1 | 2019 | 30274 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 11367 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Lung | 1 | 2018 | 31049 | 0.01 | Why? |